Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C

Molecular Medicine Reports

Volumn 7, Issue 4, 2013, Pages 1197-1202

  Wang, Dongsheng ^a   Zhou, Ding'an ^b   Du, Qin ^a   Liang, Qi ^a   Wang, Qiang ^a   Fang, Li ^a   Wang, Guangrong ^a   Fan, Quming ^a   Liu, Beizhong ^c   Zhou, Jingguo ^a   Tang, Zhong ^a   Wu, Hao ^d   Guo, Xiaolan ^a   Jiao, Yanmei ^d   Zhang, Guoyuan ^a  

^a AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

^b FUDAN UNIVERSITY   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis C; Co stimulatory molecules; Dysregulation of T cell activation; SICOS; SPD 1

Indexed keywords

INDUCIBLE T CELL COSTIMULATOR; MESSENGER RNA; PROGRAMMED DEATH 1 RECEPTOR; VIRUS ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION;

ADULT; APOPTOSIS REGULATORY PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; LIVER; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RNA, MESSENGER;

EID: 84875256095     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1326     Document Type: Article

References (25)

1. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, et al: National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 49: S4-S12, 2009.
2. Rodriguez-Luna H and Vargas HE: Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 11: 479-489, 2005.
3. Mengshol JA, Golden-Mason L and Rosen HR: Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 4: 622-634, 2007.
4. Sharpe AH and Freeman GJ: The B7-CD28 superfamily. Nat Rev Immunol 2: 116-126, 2002.
5. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P and Walker CM: Analysis of a successful immune response against hepatitis C virus. Immunity 10: 439-449, 1999.
6. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC and Chisari FV: Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194: 1395-1406, 2001.
7. + immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 44: 736-745, 2006.
8. Rehermann B, Chang KM, McHutchinson J, Kokka R, Houghton M, Rice CM and Chisari FV: Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 70: 7092-7102, 1996.
9. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M and Lau JY: The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 158: 1473-1481, 1997.
10. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C and Nelson DR: An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40: 1062-1071, 2004.
11. Yao ZQ, King E, Prayther D, Yin D and Moorman J: T cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1 signaling. Viral Immunol 20: 276-287, 2007.
12. Li S, Roberts S, Plebanski M, Gouillou M, Spelman T, Latour P, Jackson D, Brown L, Sparrow RL, Prince HM, et al: Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals. PLoS One 7: e39368, 2012.
13. + T cells during acute HCV infection, irrespective of clinical outcome. J Virol 82: 3154-3160, 2008.
14. Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, Dowd KA, Clute S, Wang C, Korman A, Sette A, et al: High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol 181: 8215-8225, 2008.
15. + T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance. J Gastroenterol Hepatol 27: 823-831, 2012.
16. Nielsen C, Ohm-Laursen L, Barington T, Husby S and Lillevang ST: Alternative splice variants of the human PD-1 gene. Cell Immunol 235: 109-116, 2005.
17. + T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci 47: 4444-4452, 2006.
18. Klenerman P and Semmo N: Cellular immune responses against persistent hepatitis C virus: gone but not forgotten. Gut 55: 914-916, 2006.
19. Koziel MJ: Cellular immune responses against hepatitis C virus. Clin Infect Dis 41 Suppl 1: S25-S31, 2005.
20. Magistrelli G, Jeannin P, Elson G, Gauchat JF, Nguyen TN, Bonnefoy JY and Delneste Y: Identification of three alternatively spliced variants of human CD28 mRNA. Biochem Biophys Res Commun 259: 34-37, 1999.
21. Nishimura H, Nose M, Hiai H, Minato N and Honjo T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141-151, 1999.
22. Greenwald RJ, Freeman GJ and Sharpe AH: The B7 family revisited. Annu Rev Immunol 23: 515-548, 2005.
23. Witsch EJ, Peiser M, Hutloff A, Buchner K, Dorner BG, Jonuleit H, Mages HW and Kroczek RA: ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur J Immunol 32: 2680-2686, 2002.
24. Warnatz K, Bossaller L, Salzer U, Skrabl-Baumgartner A, Schwinger W, van der Burg M, van Dongen JJ, Orlowska-Volk M, Knoth R, Durandy A, et al: Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 107: 3045-3052, 2006.
25. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M, Gostick E, Price DA, Freeman GJ, Wherry EJ and Chang KM: Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 5: e1000313, 2009.